Massachusetts bans Zohydro

Share this article:

Congress, 28 attorneys general, and substance abuse experts have asked the FDA to pull its approval of the painkiller Zohydro.

Massachusetts has taken another route: banning it. Reuters reports that the Bay State's governor, Deval Patrick, announced the ban during a speech Thursday in which he declared opioid abuse a New England public health emergency.

Drugmaker Zogenix decried the ban in a statement Thursday, saying, “ultimately, the ban on the prescription medication will add to patient suffering in the state.”

The company also indicated its drug has been the victim of bad, inaccurate reports. “Claims that Zohydro ER is “more powerful” or “more addictive” than other commonly prescribed opioids are not supported by scientific data, the company said.

FDA Commissioner Margaret Hamburg told lawmakers during a March 13 Senate Committee hearing that she stood by her agency's approval of the drug, yet as Bloomberg noted at the time, the FDA approval has a backdoor—the head of the anesthesia, analgesia and addiction products division said the regulator could pull the drug “if and when they, or another manufacturer, are able to create an abuse-deterrent formulation that remains safe and effective for patients.”

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.